Literature DB >> 8513959

Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.

E J Lee1, B S Lee, H C Lee, K H Park, C H Song, K B Huh.   

Abstract

OBJECTIVE: To evaluate the GH secretion and clarify the factors influencing the GH secretion in women with polycystic ovarian syndrome (PCOS).
DESIGN: Comparison of the GH response to L-dopa with or without pyridostigmine (inhibitor of acetylcholinesterase) pretreatment and insulin response to oral glucose tolerance test in patients with PCOS and matched controls.
SETTING: Outpatients and healthy volunteers studied at a clinical research unit of a university hospital. PATIENTS, PARTICIPANTS: Ten women with PCOS and 9 controls with regular cycles were recruited.
INTERVENTIONS: After an overnight fast, each subject underwent a GH stimulation test with L-dopa with or without pyridostigmine pretreatment. Plasma insulin and glucose levels were measured after a 75-g glucose load. MAIN OUTCOME MEASURES: Plasma GH, insulin-like growth factor I (IGF-I), insulin, and nonesterified fatty acids.
RESULTS: Growth hormone responses and GH area under the response curve (AUC) to L-dopa were significantly lower in PCOS than those in controls. Pyridostigmine enhanced the GH response to L-dopa significantly in PCOS. Insulin responses and insulin AUC to oral glucose load were significantly higher in PCOS than those in controls. Plasma IGF-I levels of PCOS were significantly higher than controls. Insulin AUC had a positive correlation with plasma IGF-I levels but an inverse correlation with GH AUC in PCOS and controls.
CONCLUSION: Our result indicated that decreased GH secretion of PCOS may be associated with a high somatostatin activity and a high plasma IGF-I level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513959     DOI: 10.1016/s0015-0282(16)56035-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

1.  Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome.

Authors:  G Tropeano; I Liberale; I P Vuolo; A Barini; G Caroli; P Carfagna; E Menini
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

2.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

3.  Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome.

Authors:  A Fusco; A Bianchi; A Mancini; D Milardi; A Giampietro; V Cimino; T Porcelli; D Romualdi; M Guido; A Lanzone; A Pontecorvi; L De Marinis
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 4.  Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights.

Authors:  Antonio Mancini; Carmine Bruno; Edoardo Vergani; Claudia d'Abate; Elena Giacchi; Andrea Silvestrini
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

Review 5.  Endocrinology and physiology of pseudocyesis.

Authors:  Juan J Tarín; Carlos Hermenegildo; Miguel A García-Pérez; Antonio Cano
Journal:  Reprod Biol Endocrinol       Date:  2013-05-14       Impact factor: 5.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.